<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">avk</journal-id><journal-title-group><journal-title xml:lang="ru">Архивъ внутренней медицины</journal-title><trans-title-group xml:lang="en"><trans-title>The Russian Archives of Internal Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2226-6704</issn><issn pub-type="epub">2411-6564</issn><publisher><publisher-name>“SINAPS” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20514/2226-6704-2024-14-1-38-51</article-id><article-id custom-type="edn" pub-id-type="custom">NOXREH</article-id><article-id custom-type="elpub" pub-id-type="custom">avk-1717</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group></article-categories><title-group><article-title>Частота и прогностическое значение острого перипроцедурного повреждения миокарда при плановых чрескожных коронарных вмешательствах</article-title><trans-title-group xml:lang="en"><trans-title>Frequency and Prognostic Value of Acute Periprocedural Myocardial Injury in Elective Percutaneous Coronary Interventions</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2665-9108</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Налесник</surname><given-names>Е. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Nalesnik</surname><given-names>E. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Олеговна Налесник, </p><p>Томск.</p></bio><bio xml:lang="en"><p>E.O. Nalesnik,</p><p>Tomsk.</p></bio><email xlink:type="simple">oliver@cardio-tomsk.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7123-0645</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Репин</surname><given-names>А. Н.</given-names></name><name name-style="western" xml:lang="en"><surname>Repin</surname><given-names>A. N.</given-names></name></name-alternatives><bio xml:lang="ru"><p>А. Н. Репин, </p><p>Томск.</p></bio><bio xml:lang="en"><p>A.N. Repin,</p><p>Tomsk.</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Научно-исследовательский институт кардиологии — филиал Федерального государственного бюджетного научного учреждения «Томский национальный исследовательский медицинский центр Российской академии наук», Отделение амбулаторной кардиологии</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cardiology Research Institute, branch of the Federal State Budgetary Scientific Institution «Tomsk National Research Medical Center of the Russian Academy of Sciences», Department of Ambulatory Cardiology</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2024</year></pub-date><pub-date pub-type="epub"><day>13</day><month>02</month><year>2024</year></pub-date><volume>14</volume><issue>1</issue><fpage>38</fpage><lpage>51</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Налесник Е.О., Репин А.Н., 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="ru">Налесник Е.О., Репин А.Н.</copyright-holder><copyright-holder xml:lang="en">Nalesnik E.O., Repin A.N.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.medarhive.ru/jour/article/view/1717">https://www.medarhive.ru/jour/article/view/1717</self-uri><abstract><p>Обоснование. Острое повреждение миокарда (ОПМ) является перипроцедурным осложнением чрескожных коронарных вмешательств (ЧКВ) у пациентов со стабильной ишемической болезнью сердца. Его частота и связь с прогнозом заболевания особенно важны в связи с низким риском ишемических событий в этой когорте пациентов. Тем не менее, по данным литературы существуют значительные различия в критериях ОПМ и инфарктом миокарда (ИМ) 4а типа, и, соответственно, их частоте и их прогностическом значении. Цель. Изучить частоту и величину ОПМ при плановых ЧКВ по уровню перипроцедурного повышения кардиоспецифических ферментов (КСФ), а также определить связь ОПМ с отдаленными неблагоприятными событиями у пациентов с хронической коронарной болезнью сердца. Материалы и методы. Проведено одноцентровое открытое ретроспективное когортное исследование, включившее 435 пациентов (367/84,4 % мужчин, средний возраст 58,3±8,6 лет) из регистра плановых ЧКВ, у которых была отслежена динамика КСФ в перипроцедурный период. ОПМ диагностировалось при повышении уровня МВ фракции креатинфосфокиназы (CK-MB) или сердечного тропонина I (cTn I) &gt;1×99 перцентиль URL (Upper Reference Limit — верхний референтный предел), при этом регистрировался уровень повышения КСФ &gt;1, 2, 3, 4 или &gt;5×99 перцентиль URL. Повышение КСФ &gt;5×99 перцентиль URL оценивалось как значительное ОПМ, а при наличии клинических и визуализирующих доказательств новой потери жизнеспособного миокарда — как перипроцедурный ИМ. Далее был рассчитан относительный риск (RR) отдаленных неблагоприятных сердечно-сосудистых осложнений, смерти, а также клинически значимых кровотечений и вновь диагностированных злокачественных онкологических заболеваний в течение 5 лет после индексных ЧКВ в зависимости от уровня пери процедурного повышения КСФ. Корреляция между ОПМ и вышеперечисленными конечными точками была обобщена с помощью анализа Каплана-Мейера. Результаты. Частота перипроцедурного ОПМ, диагностированного по повышению КСФ &gt;1х99 перцентиль URL составила 40,2 %, &gt;2×99 перцентиль URL — 9,7 %, &gt;3×99 перцентиль URL — 6,7 %, &gt;4×99 перцентиль URL — 4,8 %, &gt;5×99 перцентиль URL — 3,5 %, ИМ 4а типа — у 2 пациентов (0,46 %). Выявлена ассоциация «большого» ОПМ (&gt;5х99 перцентиль URL) с сердечно-сосудистыми осложнениями, в том числе и смертельными, в течение 3-х лет после планового ЧКВ: для острого инфаркта миокарда (ОИМ) RR составил 6,516, доверительный интервал (СI) [2.375-17.881]; для смерти от сердечно-сосудистых причин RR — 6,538, CI [1.695-25.227]. Показана ассоциация «умеренного» ОПМ (&gt;3, но &lt;5 ×99 перцентиль URL) с острыми ишемическими собы тиями в течение 3-х лет после планового ЧКВ: для ОИМ RR составил 4,073, CI [1.598-10.378]. Выявлена ассоциация «незначительного» ОПМ (&gt;1, но &lt;3 ×99 перцентиль URL) с вновь диагностированными злокачественными онкологическими заболеваниями в течение 5 лет после индексного ЧКВ: RR 2,319; CI [1.248-4.310]. Выявлена ассоциация отдаленных тромботических событий, таких как тромбоз стентов (индексных и установленных при повторных вмешательствах), окклюзии стентов (индексных и неиндексных) как причины повторного вмешательства в течение 5 лет после индексного ЧКВ — с большинством подгрупп ОПМ. Анализ Каплана-Мейера выявил зависимость клинически значимых кровотечений в течение 5 лет после индексного ЧКВ от развития «умеренного» ОПМ (р=0,003), а также ассоциацию не сердечно-сосудистой смерти в течение 5 лет после индексного ЧКВ с «незначительным» ОПМ (р=0,007). Заключение. Регистрация уровня перипроцедурного повышения КСФ должна проводится при плановых ЧКВ не только с целью диагностики и прогнозирования острых и отдаленных ишемических событий, но и для оценки риска развития окклюзии стентов, клинически значимых кровотечений, прогностически важной сопутствующей патологии и смерти в отдаленный (5-летний) период с целью выделения групп пациентов, требующих активного наблюдения, дополнительного обследования и подбора схемы оптимального лечения на амбулаторном этапе реабилитации.</p></abstract><trans-abstract xml:lang="en"><p>Background. Periprocedural myocardial injury (PMI) is an acute complication of percutaneous coronary interventions (PCI) in patients with stable coronary artery disease. Its frequency and relationship with the prognosis of the disease are especially important in elective interventions due to the low risk of ischemic events in this cohort of patients. However, according to the literature, there are significant differences in the criteria for PMI and type 4a myocardial infarction (MI), and, accordingly, their frequency and their prognostic value. Aim. To study the frequency and magnitude of PMI during elective PCI in terms of the level of periprocedural increase in cardiospecific biomarkers, as well as to determine the relationship of PMI with long-term adverse events in patients with chronic coronary artery disease. Materials and methods. A single-center open retrospective cohort study was conducted, which included 435 patients (367/84.4 % men, mean age 58.3±8.6 years) from the elective PCI registry. PMI was diagnosed with an increase in the level of creatine phosphokinase MB fraction (CK-MB) or or cardiac troponin I (cTn I) &gt;1×99 percentile URL (Upper Reference Limit), while the level of increase in biomarkers &gt;1, 2, 3, 4 or &gt;5×99 percentile URL was recorded. An increase in biomarkers &gt;5x99 URL percentile was assessed as a large PMI, and in the presence of clinical and imaging evidence of new loss of viable myocardium, as periprocedural MI type 4a. Depending on the level of periprocedural increase in biomarkers, the relative risk (RR) of developing long-term (within 5 years after index PCI) adverse cardiovascular events, death, as well as clinically significant bleeding and newly diagnosed malignant oncological diseases was calculated. In addition, the correlation between PMI and the above endpoints was summarized using Kaplan-Meier analysis. Results. The frequency of periprocedural PMI diagnosed by increased biomarkers &gt;1×99 percentile URL was 40.2 %, &gt;2×99 percentile URL — 9.7 %, &gt;3×99 percentile URL — 6.7 %, &gt;4×99 percentile URL — 4.8 %, &gt;5×99 percentile URL — 3.5 %, type 4a MI — in 2 patients (0.46 %). An association of “major” PMI (&gt;5x99 percentile URL) with cardiovascular complications within 3 years after elective PCI, including fatal ones, was revealed: for acute myocardial infarction (AMI), RR — 6.516, confidence interval (CI) [2.375-17.881]; for death from cardiovascular causes RR — 6.538, CI [1.695-25.227]. An association of “moderate” PMI (&gt;3, but &lt;5 ×99 URL percentile) with acute ischemic events within 3 years after elective PCI was shown: for AMI, RR was 4.073, CI [1.598 — 10.378]. An association of “minor” AKI (&gt;1, but &lt;5 ×99 URL percentile) with acute ischemic events within 3 years after elective PCI was shown: for AMI, RR was 4.073, CI [1.598 — 10.378]. An association of “minor” AKI (&gt;1, but &lt;3 ×99 URL percentile) with newly diagnosed malignant oncological diseases within 5 years after index PCI was revealed: RR 2.319; CI [1.248- 4.310]. An association of late thrombotic events, such as stent thrombosis (index and re-interventions), stent occlusion (index and non-index) as a reason for re-intervention within 5 years after index PCI, was found with most PMI subgroups. Kaplan-Meier analysis of the dependence of clinically significant bleeding within 5 years after index PCI on the development of “moderate” PMI (p=0.003), as well as the association of non-cardiovascular death within 5 years after index PCI with “minor” PMI (p= 0.007). Conclusion. Registration of periprocedural increase in cardiac biomarkers should be carried out during planned PCI not only for the purpose of diagnosing and predicting acute and late ischemic events, but also for assessing the risk of developing stent occlusion, clinically significant bleeding and prognostically important comorbidities in the long-term (5-year) period in order to identification of groups of patients requiring active monitoring, additional examination and selection of an optimal treatment regimen at the outpatient stage of rehabilitation.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ишемическая болезнь сердца</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>перипроцедурное повреждение миокарда</kwd><kwd>МВ фракция креатинфосфокиназы</kwd><kwd>сердечный тропонин</kwd></kwd-group><kwd-group xml:lang="en"><kwd>ischemic heart disease</kwd><kwd>percutaneous coronary intervention</kwd><kwd>periprocedural myocardial injury</kwd><kwd>сreatine kinase-MB</kwd><kwd>cardiac troponin</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е.О., Репин А.Н. Предикторы отдаленных фатальных сердечно-сосудистых событий после плановых чрескожных коронарных вмешательств. Российский кардиологический журнал. 2018; (11): 34-43. DOI: 10.15829/1560-4071-2018-11-34-43</mixed-citation><mixed-citation xml:lang="en">Vershinina E.O., Repin A.N. Predictors of long-term fatal cardiovascular events after planned percutaneous coronary interventions. Rossiiskii kardiologicheskij zhurnal. 2018; (11): 34-43 DOI: 10.15829/1560-4071-2018-11-34-43 [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Park D, Kim Y, Yun S, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013; 34(22): 1662–1669. DOI: 10.1093/eurheartj/eht048</mixed-citation><mixed-citation xml:lang="en">Park D, Kim Y, Yun S, et al. Frequency, causes, predictors, and clinical significance of peri-procedural myocardial infarction following percutaneous coronary intervention. Eur Heart J. 2013; 34(22): 1662–1669. DOI: 10.1093/eurheartj/eht048</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Zeitouni M, Silvain J, Guedeney P, et al. for the ACTION Study Group. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018; 39(13): 1100–1109. DOI: 10.1093/eurheartj/ehx799</mixed-citation><mixed-citation xml:lang="en">Zeitouni M, Silvain J, Guedeney P, et al. for the ACTION Study Group. Periprocedural myocardial infarction and injury in elective coronary stenting. Eur Heart J. 2018; 39(13): 1100–1109. DOI: 10.1093/eurheartj/ehx799</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е.О., Сальникова Е.С., Репин А.Н. Профилактика острого повреждения миокарда при плановых эндоваскулярных вмешательствах на коронарных артериях. Сибирский журнал клинической и экспериментальной медицины. 2015; 30(2): 87-96.</mixed-citation><mixed-citation xml:lang="en">Vershinina EO, Salnikova ES, Repin AN. Prevention of acute myocardial damage in elective percutaneous coronary interventions. Sib J Clin Exp Med. 2015; 30(2): 87-96. [In Russian]</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance after Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: a Report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008; 51(21): 2068–2074. DOI: 10.1016/j.jacc.2008.01.054</mixed-citation><mixed-citation xml:lang="en">Wang TY, Peterson ED, Dai D, et al. Patterns of Cardiac Marker Surveillance after Elective Percutaneous Coronary Intervention and Implications for the Use of Periprocedural Myocardial Infarction as a Quality Metric: a Report from the National Cardiovascular Data Registry (NCDR). J Am Coll Cardiol. 2008; 51(21): 2068–2074. DOI: 10.1016/j.jacc.2008.01.054</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque Volume and Occurrence and Location of Periprocedural Myocardial Necrosis after Percutaneous Coronary Intervention: insights from delayed enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation. 2006; 114(7): 662–669. DOI: 10.1161/CIRCULATIONAHA.105.593210</mixed-citation><mixed-citation xml:lang="en">Porto I, Selvanayagam JB, Van Gaal WJ, et al. Plaque Volume and Occurrence and Location of Periprocedural Myocardial Necrosis after Percutaneous Coronary Intervention: insights from delayed enhancement magnetic resonance imaging, Thrombolysis in Myocardial Infarction myocardial perfusion grade analysis, and intravascular ultrasound. Circulation. 2006; 114(7): 662–669. DOI: 10.1161/CIRCULATIONAHA.105.593210</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. Circulation. 2012; 126(16): 2020–2035. DOI: 10.1161/CIR.0b013e31826e1058</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Alpert JS, Jaffe AS, et al. Third Universal Definition of Myocardial Infarction. Circulation. 2012; 126(16): 2020–2035. DOI: 10.1161/CIR.0b013e31826e1058</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Moussa ID, Klein LW, Shah B, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013; 62(17): 1563–70. DOI: 10.1016/j.jacc.2013.08.720</mixed-citation><mixed-citation xml:lang="en">Moussa ID, Klein LW, Shah B, et al. Consideration of a new definition of clinically relevant myocardial infarction after coronary revascularization: an expert consensus document from the Society for Cardiovascular Angiography and Interventions (SCAI). J Am Coll Cardiol. 2013; 62(17): 1563–70. DOI: 10.1016/j.jacc.2013.08.720</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Alpert JS, Jaffe AS, et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231-2264. doi: 10.1016/j.jacc.2018.08.1038.</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Alpert JS, Jaffe AS, et al; Executive Group on behalf of the Joint European Society of Cardiology (ESC)/American College of Cardiology (ACC)/American Heart Association (AHA)/World Heart Federation (WHF) Task Force for the Universal Definition of Myocardial Infarction. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018; 72(18): 2231-2264. doi: 10.1016/j.jacc.2018.08.1038.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Bulluck H, Paradies V, Barbato E, et al. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2021; 42(27):2 630-2642. DOI: 10.1093/eurheartj/ehab271.</mixed-citation><mixed-citation xml:lang="en">Bulluck H, Paradies V, Barbato E, et al. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2021; 42(27):2 630-2642. DOI: 10.1093/eurheartj/ehab271.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Garcia HM, McFadden EP, von Birgelen C, et al. Impact of periprocedural myocardial biomarker elevation on mortality following elective percutaneous coronary intervention. JACC Cardiovasc Interv 2019; 12(19): 1954–1962. DOI: 10.1016/j.jcin.2019.07.014</mixed-citation><mixed-citation xml:lang="en">Garcia-Garcia HM, McFadden EP, von Birgelen C, et al. Impact of periprocedural myocardial biomarker elevation on mortality following elective percutaneous coronary intervention. JACC Cardiovasc Interv 2019; 12(19): 1954–1962. DOI: 10.1016/j.jcin.2019.07.014</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Yang X, Tamez H, Lai C, et al. Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. Catheter Cardiovasc Interv. 2017; 89(5): 849–856. DOI: 10.1002/ccd.26688</mixed-citation><mixed-citation xml:lang="en">Yang X, Tamez H, Lai C, et al. Type 4a myocardial infarction: Incidence, risk factors, and long-term outcomes. Catheter Cardiovasc Interv. 2017; 89(5): 849–856. DOI: 10.1002/ccd.26688</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ndrepepa G, Colleran R, Braun S, et al. High-Sensitivity Troponin T and Mortality after Elective Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016; 68(21): 2259–2268. DOI: 10.1016/j.jacc.2016.08.059</mixed-citation><mixed-citation xml:lang="en">Ndrepepa G, Colleran R, Braun S, et al. High-Sensitivity Troponin T and Mortality after Elective Percutaneous Coronary Intervention. J Am Coll Cardiol. 2016; 68(21): 2259–2268. DOI: 10.1016/j.jacc.2016.08.059</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Bangalore S, Pencina MJ, Kleiman NS, et al. Prognostic implications of procedural vs spontaneous myocardial infarction: Results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Am Heart J. 2013; 166(6): 1027–1034. DOI: 10.1016/j.ahj.2013.09.008</mixed-citation><mixed-citation xml:lang="en">Bangalore S, Pencina MJ, Kleiman NS, et al. Prognostic implications of procedural vs spontaneous myocardial infarction: Results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. Am Heart J. 2013; 166(6): 1027–1034. DOI: 10.1016/j.ahj.2013.09.008</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Вершинина Е.О., Репин А.Н. Отдаленные исходы плановых эндоваскулярных вмешательств на коронарных артериях. Кардиология. 2018;58(7):5–13. DOI: 10.18087/cardio.2018.7.10137</mixed-citation><mixed-citation xml:lang="en">Vershinina E.O., Repin А.N. Long-term Outcomes of Elective Percutaneous Coronary Interventions. Kardiologiia. 2018;58(7):5–13. DOI: 10.18087/cardio.2018.7.10137 [In Russian].</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120(4): c179-84. DOI: 10.1159/000339789.</mixed-citation><mixed-citation xml:lang="en">Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012; 120(4): c179-84. DOI: 10.1159/000339789.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007; 28(20): 2525–2538. DOI: 10.1093/eurheartj/ehm355</mixed-citation><mixed-citation xml:lang="en">Thygesen K, Alpert JS, White HD. Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J. 2007; 28(20): 2525–2538. DOI: 10.1093/eurheartj/ehm355</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Garcia-Garcia HM, McFadden EP, Farb A, et al; Academic Research Consortium. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Eur Heart J. 2018; 39(23): 2192–2207. DOI: 10.1093/eurheartj/ehy223</mixed-citation><mixed-citation xml:lang="en">Garcia-Garcia HM, McFadden EP, Farb A, et al; Academic Research Consortium. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Eur Heart J. 2018; 39(23): 2192–2207. DOI: 10.1093/eurheartj/ehy223</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Ueki Y, Otsuka T, Bär S, et al. Frequency and Outcomes of Periprocedural MI in Patients with Chronic Coronary Syndromes Undergoing PCI. J Am Coll Cardiol. 2022; 79(6): 513–526. DOI: 10.1016/j.jacc.2021.11.047</mixed-citation><mixed-citation xml:lang="en">Ueki Y, Otsuka T, Bär S, et al. Frequency and Outcomes of Periprocedural MI in Patients with Chronic Coronary Syndromes Undergoing PCI. J Am Coll Cardiol. 2022; 79(6): 513–526. DOI: 10.1016/j.jacc.2021.11.047</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Herrmann J, Lennon RJ, Jaffe AS, et al. Defining the optimal cardiac troponin T threshold for predicting death caused by periprocedural myocardial infarction after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014; 7(4): 533–542. DOI: 10.1161/CIRCINTERVENTIONS.113.000544</mixed-citation><mixed-citation xml:lang="en">Herrmann J, Lennon RJ, Jaffe AS, et al. Defining the optimal cardiac troponin T threshold for predicting death caused by periprocedural myocardial infarction after percutaneous coronary intervention. Circ Cardiovasc Interv. 2014; 7(4): 533–542. DOI: 10.1161/CIRCINTERVENTIONS.113.000544</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Loeb HS, Liu JC. Frequency, risk factors, and effect on long-term survival of increased troponin I following uncomplicated elective percutaneous coronary intervention. Clin Cardiol 2010; 33(12): E40–E44. DOI: 10.1002/clc.20425</mixed-citation><mixed-citation xml:lang="en">Loeb HS, Liu JC. Frequency, risk factors, and effect on long-term survival of increased troponin I following uncomplicated elective percutaneous coronary intervention. Clin Cardiol 2010; 33(12): E40–E44. DOI: 10.1002/clc.20425</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Cottens D, Maeremans J, McCutcheon K, et al. Prognostic value of the high-sensitivity troponin T assay after percutaneous intervention of chronic total occlusions. J Cardiovasc Med (Hagerstown) 2018; 19(7): 366–372. DOI: 10.2459/JCM.0000000000000660</mixed-citation><mixed-citation xml:lang="en">Cottens D, Maeremans J, McCutcheon K, et al. Prognostic value of the high-sensitivity troponin T assay after percutaneous intervention of chronic total occlusions. J Cardiovasc Med (Hagerstown) 2018; 19(7): 366–372. DOI: 10.2459/JCM.0000000000000660</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010; 3(6): 602–610. DOI: 10.1161/CIRCINTERVENTIONS.110.959080</mixed-citation><mixed-citation xml:lang="en">Lansky AJ, Stone GW. Periprocedural myocardial infarction: prevalence, prognosis, and prevention. Circ Cardiovasc Interv. 2010; 3(6): 602–610. DOI: 10.1161/CIRCINTERVENTIONS.110.959080</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Babu GG, Walker JM, Yellon DM, et al. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J. 2011; 32(1): 23–31. DOI: 10.1093/eurheartj/ehq393</mixed-citation><mixed-citation xml:lang="en">Babu GG, Walker JM, Yellon DM, et al. Peri-procedural myocardial injury during percutaneous coronary intervention: an important target for cardioprotection. Eur Heart J. 2011; 32(1): 23–31. DOI: 10.1093/eurheartj/ehq393</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Ishibashi Y, Muramatsu T, Nakatani S, et al. Incidence and potential mechanism(s) of post-procedural rise of cardiac biomarker in patients with coronary artery narrowing after implantation of an everolimuseluting bioresorbable vascular scaffold or everolimuseluting metallic stent. JACC Cardiovasc Interv. 2015; 8(8): 1053–1063. DOI: 10.1016/j.jcin.2015.06.001</mixed-citation><mixed-citation xml:lang="en">Ishibashi Y, Muramatsu T, Nakatani S, et al. Incidence and potential mechanism(s) of post-procedural rise of cardiac biomarker in patients with coronary artery narrowing after implantation of an everolimuseluting bioresorbable vascular scaffold or everolimuseluting metallic stent. JACC Cardiovasc Interv. 2015; 8(8): 1053–1063. DOI: 10.1016/j.jcin.2015.06.001</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Choi CJ, Haji-Momenian S, Dimaria JM, et al. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. J Cardiovasc Magn Reson. 2004; 6(4):917–925. DOI: 10.1081/jcmr-200036206</mixed-citation><mixed-citation xml:lang="en">Choi CJ, Haji-Momenian S, Dimaria JM, et al. Infarct involution and improved function during healing of acute myocardial infarction: the role of microvascular obstruction. J Cardiovasc Magn Reson. 2004; 6(4):917–925. DOI: 10.1081/jcmr-200036206</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Kini AS, Motoyama S, Vengrenyuk Y, et al. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015; 8(7):937-45. DOI: 10.1016/j.jcin.2015.03.016.</mixed-citation><mixed-citation xml:lang="en">Kini AS, Motoyama S, Vengrenyuk Y, et al. Multimodality Intravascular Imaging to Predict Periprocedural Myocardial Infarction During Percutaneous Coronary Intervention. JACC Cardiovasc Interv. 2015; 8(7):937-45. DOI: 10.1016/j.jcin.2015.03.016.</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J. 2006; 27(9): 1061–1069. DOI: 10.1093/eurheartj/ehi760</mixed-citation><mixed-citation xml:lang="en">Miller WL, Garratt KN, Burritt MF, et al. Baseline troponin level: key to understanding the importance of post-PCI troponin elevations. Eur Heart J. 2006; 27(9): 1061–1069. DOI: 10.1093/eurheartj/ehi760</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008; 1(1): 10–19. DOI: 10.1161/CIRCINTERVENTIONS.108.765610</mixed-citation><mixed-citation xml:lang="en">Prasad A, Rihal CS, Lennon RJ, et al. Significance of periprocedural myonecrosis on outcomes after percutaneous coronary intervention: an analysis of preintervention and postintervention troponin T levels in 5487 patients. Circ Cardiovasc Interv. 2008; 1(1): 10–19. DOI: 10.1161/CIRCINTERVENTIONS.108.765610</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Silvain J, Zeitouni M, Paradies V, et al. Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patientlevel data. Eur Heart J. 2021; 42(14): 323–334. DOI: 10.1093/eurheartj/ehaa885</mixed-citation><mixed-citation xml:lang="en">Silvain J, Zeitouni M, Paradies V, et al. Cardiac procedural myocardial injury, infarction, and mortality in patients undergoing elective percutaneous coronary intervention: a pooled analysis of patientlevel data. Eur Heart J. 2021; 42(14): 323–334. DOI: 10.1093/eurheartj/ehaa885</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
